日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Low-penetrance TP53 variants are mainly hypomorphic: an underestimated issue with high clinical significance

低外显率的TP53变异体主要为功能减弱型:这是一个被低估但具有重要临床意义的问题。

Rodriguez, Lea; Leroy, Bernard; Toledo, Franck; Funk, Julianne Susanne; Stiewe, Thorsten; Baliakas, Panagiotis; Delhommeau, François; Soussi, Thierry

Oncogenic and teratogenic effects of Trp53(Y217C), an inflammation-prone mouse model of the human hotspot mutant TP53(Y220C).

Trp53(Y217C) 的致癌和致畸作用,是人类热点突变体 TP53(Y220C) 的炎症易感小鼠模型

Jaber Sara, Eldawra Eliana, Rakotopare Jeanne, Simeonova Iva, Lejour Vincent, Gabriel Marc, Cañeque Tatiana, Volochtchouk Vitalina, Licaj Monika, Fajac Anne, Rodriguez Raphaël, Morillon Antonin, Bardot Boris, Toledo Franck

Mutant p53 as a Therapeutic Target: The Report of Its Death Was an Exaggeration

突变型p53作为治疗靶点:关于其“死亡”的报道被夸大了

Toledo, Franck

Mechanisms Generating Cancer Genome Complexity: Back to the Future

癌症基因组复杂性的产生机制:回到未来

Toledo, Franck

Fuzzy tandem repeats containing p53 response elements may define species-specific p53 target genes.

含有 p53 反应元件的模糊串联重复序列可能定义物种特异性的 p53 靶基因

Simeonova Iva, Lejour Vincent, Bardot Boris, Bouarich-Bourimi Rachida, Morin Aurélie, Fang Ming, Charbonnier Laure, Toledo Franck

MDM2 and MDM4: p53 regulators as targets in anticancer therapy

MDM2 和 MDM4:p53 调节因子作为抗癌治疗的靶点

Toledo, Franck; Wahl, Geoffrey M

Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression

小鼠突变体表明,p53富含脯氨酸结构域中假定的蛋白质相互作用位点对于肿瘤抑制并非必需。

Toledo, Franck; Lee, Crystal J; Krummel, Kurt A; Rodewald, Luo-Wei; Liu, Chung-Wen; Wahl, Geoffrey M

RMCE-ASAP: a gene targeting method for ES and somatic cells to accelerate phenotype analyses

RMCE-ASAP:一种用于ES细胞和体细胞的基因靶向方法,可加速表型分析

Toledo, Franck; Liu, Chung-Wen; Lee, Crystal J; Wahl, Geoffrey M